Piper Sandler Reiterates Overweight Rating on Neurocrine Bio. (NBIX) Following FDA Approval of Elagolix
Tweet Send to a Friend
Piper Sandler analyst David Amsellem reiterated an Overweight rating and $126.00 price target on Neurocrine Bio. (NASDAQ: NBIX) following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
